Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225938 | 1.00 | MEN1 (0.42) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL13127917 | 0.83 | HTT (0.46) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL19243702 | 0.80 | ALDH1A1 (0.45) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL26319653 | 0.80 | FFAR2 (0.41) | MEN1NPC1RAB9AKMT2ALMNA | |
| Isaxonine SCHEMBL9030532 | 0.79 | PKM (0.40) | MEN1NPC1RAB9AKMT2ALMNA | |
| Isaxonine SCHEMBL2846192 | 0.78 | MAPK1 (0.48) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL6811033 | 0.77 | POLB (0.55) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL44234 | 0.77 | POLB (0.55) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL44233 | 0.77 | POLB (0.55) | MEN1NPC1RAB9AKMT2ALMNA | |
| SCHEMBL503092 | 0.77 | POLB (0.55) | MEN1NPC1RAB9AKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145067-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-25 | — | — | US | disclosed |
| US-9605042-B2 | Compositions and methods related to tauopathy | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160152675-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-06-02 | — | — | US | disclosed |
| US-9200068-B2 | Compositions and methods related to tauopathy | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140171373-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2459727-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| WO-2011012632-A2 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | BASF SE (DE) | 2011-02-03 | — | — | WO | disclosed |
| EP-2280075-A1 | Biocatalyst for catalytic hydroamination | BASF SE (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20090011400-A1 | Substrate switched ammonia lyases and mutases | The Salk Institute for Biological Studies and The Regents of the University of California | 2009-01-08 | — | — | US | disclosed |
| WO-2008069958-A2 | SUBSTRATE SWITCHED AMMONIA LYASES AND MUTASES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171373-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | PSEN2, PSEN1, CASP2 | MEN1 2200/4885NPC1 2791/4885RAB9A 4099/4885 |
| US-20120123155-A1 | BIOCATALYST FOR CATALYTIC HYDROAMINATION | HDHD5, PAH, GRHPR | MEN1 3127/4885NPC1 2831/4885RAB9A 3509/4885 |
| US-20160152675-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | PSEN2, PSEN1, CASP2 | MEN1 2200/4885NPC1 2791/4885RAB9A 4099/4885 |
| US-20170145067-A1 | COMPOSITIONS AND METHODS RELATED TO TAUOPATHY | PSEN2, PSEN1, CASP2 | MEN1 2200/4885NPC1 2791/4885RAB9A 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.